Companies › OncoVerity
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cusatuzumab CD70 antigen inhibitor | CD70 | Phase 2 | Leukemia, Myeloid, Acute | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06384261 | Cusatuzumab | Phase 2 | Leukemia, Myeloid, Acute | Oncology | Jan 2027 |
| NCT04023526 | Cusatuzumab | Phase 2 | Leukemia, Myeloid, Acute | Oncology | May 2027 |
| NCT04150887 | Cusatuzumab | Phase 1 | Leukemia, Myeloid, Acute | Oncology | May 2027 |
Chongqing Precision Biotech Allogene Therapeutics Pfizer Beijing Biotech Alpine Immune Sciences Qilu Pharmaceutical Hrain Biotechnology Adicet Therapeutics
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.